Medigus Ltd ADR Alpha and Beta Analysis
| MDGSDelisted Stock | USD 1.73 0.01 0.58% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Medigus Ltd ADR. It also helps investors analyze the systematic and unsystematic risks associated with investing in Medigus over a specified time horizon. Remember, high Medigus' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Medigus' market risk premium analysis include:
Beta (1.87) | Alpha (0.24) | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Medigus |
Medigus Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Medigus market risk premium is the additional return an investor will receive from holding Medigus long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Medigus. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Medigus' performance over market.| α | -0.24 | β | -1.87 |
Medigus Fundamentals Vs Peers
Comparing Medigus' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Medigus' direct or indirect competition across all of the common fundamentals between Medigus and the related equities. This way, we can detect undervalued stocks with similar characteristics as Medigus or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Medigus' fundamental indicators could also be used in its relative valuation, which is a method of valuing Medigus by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Medigus to competition |
| Fundamentals | Medigus | Peer Average |
| Return On Equity | -0.31 | -0.31 |
| Return On Asset | -0.0663 | -0.14 |
| Profit Margin | (0.13) % | (1.27) % |
| Operating Margin | (0.09) % | (5.51) % |
| Current Valuation | 65.3 M | 16.62 B |
| Shares Outstanding | 1.89 M | 571.82 M |
| Shares Owned By Institutions | 0.29 % | 39.21 % |
Medigus Opportunities
Medigus Return and Market Media
The Stock received some media coverage during the period. Price Growth (%) |
| Timeline |
1 | Medigus Revoltz Initiates on Exclusive Distribution Agreement of 2.7 Million in Revenues and Completes the Production of the First 50 PORTO Micro-Mobility EVs | 03/27/2024 |
2 | Medigus subsidiary completes wireless EV charging system | 04/01/2024 |
3 | Medigus to rebrand as Xylo Technologies with new Nasdaq ticker | 04/09/2024 |
About Medigus Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Medigus or other delisted stocks. Alpha measures the amount that position in Medigus Ltd ADR has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Medigus Upcoming Company Events
As portrayed in its financial statements, the presentation of Medigus' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Medigus' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Medigus' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Medigus. Please utilize our Beneish M Score to check the likelihood of Medigus' management manipulating its earnings.
| 2nd of May 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 2nd of May 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Medigus
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Medigus Stock
If you are still planning to invest in Medigus Ltd ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Medigus' history and understand the potential risks before investing.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |